中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.016 seconds)

    METHOD FOR FIRST-LINE TREATMENT OF ROSACEA
    4.
    发明申请
    METHOD FOR FIRST-LINE TREATMENT OF ROSACEA 审中-公开

    公开(公告)号：US20200261398A1

    公开(公告)日：2020-08-20

    申请号：US16794809

    申请日：2020-02-19

    Applicant: Sol-Gel Technologies Ltd.

    Inventor： Moshe ARKIN ,  Karine NEIMANN ,  Ofer TOLEDANO

    IPC: A61K31/327 ,  A61K9/107 ,  A61K9/06 ,  A61P17/10

    Abstract: A first-line treatment regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition including from about 1% to about 10% benzoyl peroxide as the sole active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, the primary measure of success being defined as a 2-grade improvement in Investigator Global Assessment (IGA) of clear or almost clear, and a secondary measure of success of at least about 40%, the secondary measure of success being defined as a percentage decrease the in the number of inflammatory lesions, and said pharmaceutical composition is applied once daily for a period of at least about 2 weeks.

    METHOD OF ACNE TREATMENT BY CONCOMITANT TOPICAL ADMINISTRATION OF BENZOYL PEROXIDE AND TRETINOIN
    5.
    发明申请
    METHOD OF ACNE TREATMENT BY CONCOMITANT TOPICAL ADMINISTRATION OF BENZOYL PEROXIDE AND TRETINOIN 审中-公开

    公开(公告)号：US20190015368A1

    公开(公告)日：2019-01-17

    申请号：US15647331

    申请日：2017-07-12

    Applicant: SOL-GEL TECHNOLOGIES LTD.

    Inventor： Moshe ARKIN ,  Stephen CHERKEZ ,  Ofer TOLEDANO

    IPC: A61K31/203 ,  A61K31/327 ,  A61K9/00 ,  A61K9/50 ,  A61K47/14

    Abstract: The present disclosure relates to methods of treatment of acne in a patient in need thereof, comprising the concomitant once daily topical administration of from about 2% w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) for a period of up to 3 months, wherein the side-effects of the two actives are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active administered alone. The concomitant administration may be carried out by once daily administration to a patient in need thereof of a single composition or of a first composition comprising BPO and a second composition comprising ATRA from a dual chamber dispenser or from two separate dispensers, mixed before applying on the skin of a patient in need thereof for up to 2 weeks, up to 1 month, preferably up to 2 months and more preferably up to 3 months.

    TREATMENT OF PSORIASIS WITH TOPICAL TAPINAROF-TAZAROTENE COMBINATION COMPOSITIONS
    8.
    发明申请
    TREATMENT OF PSORIASIS WITH TOPICAL TAPINAROF-TAZAROTENE COMBINATION COMPOSITIONS 有权

    公开(公告)号：US20220054467A1

    公开(公告)日：2022-02-24

    申请号：US17432927

    申请日：2020-02-25

    Applicant: Sol-Gel Technologies Ltd.

    Inventor： Moshe ARKIN

    IPC: A61K31/4436 ,  A61K31/05 ,  A61K9/00 ,  A61K9/06 ,  A61K47/44 ,  A61K47/10 ,  A61K47/20 ,  A61K47/18 ,  A61K47/32 ,  A61K47/12 ,  A61K47/02 ,  A61K45/06

    Abstract: Provided herein is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w tazarotene and a carrier suitable for topical administration. Also provided is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w w tazarotene, from about 0.01% w/w to about 0.25% w/w at least one corticosteroid of potency class 1-4 and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of plaque psoriasis and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions. The addition of tazarotene to tapinarof potentiates the tapinarof anti-psoriatic therapeutic effect.

    TREATMENT OF SKIN DISORDERS WITH TOPICAL TAPINAROF COMBINATION COMPOSITIONS
    9.
    发明申请
    TREATMENT OF SKIN DISORDERS WITH TOPICAL TAPINAROF COMBINATION COMPOSITIONS 有权

    公开(公告)号：US20220008356A1

    公开(公告)日：2022-01-13

    申请号：US17425956

    申请日：2020-01-27

    Applicant: Sol-Gel Technologies Ltd.

    Inventor： Moshe ARKIN

    IPC: A61K31/05 ,  A61K9/00 ,  A61K31/573 ,  A61K31/593 ,  A61K9/06 ,  A61K31/519

    Abstract: Provided herein are topical combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.

Patent Agency Ranking